20-Hydroxyvitamin D3
20-Hydroxyvitamin D3 (20(OH)D3), a product of vitamin D3 hydroxylation, is a noncalcemic immunomodulator. 20-Hydroxyvitamin D3 binds to vitamin D receptor (VDR), activates VDR and aryl hydrocarbon receptor (AhR) signaling, stimulates CYP24A1 expression, and drives VDR nuclear translocation. 20-Hydroxyvitamin D3 inhibits NF-κB activity via IκBα upregulation. 20-Hydroxyvitamin D3 acts as a substrate for CYP27B1 and rat CYP24A1, undergoing hydroxylation to form dihydroxy-derivatives. 20-Hydroxyvitamin D3 inhibits cell proliferation, colony formation, migration, and tumor growth, and induces cell differentiation in cancer cells. 20-Hydroxyvitamin D3 can be used for the research of inflammatory and autoimmune diseases, melanoma, breast carcinomas, and hepatocarcinoma.
For research use only. We do not sell to patients.
- CAS No.: 651734-12-2
- Formula: C27H44O2
- Molecular Weight:400.64
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
0.454 nM
Compound: 20S(OH)D3
|
Antiproliferative activity against NHEK cells incubated for 24 hrs by [3H]thymidine incorporation assay
Antiproliferative activity against NHEK cells incubated for 24 hrs by [3H]thymidine incorporation assay
|
[PMID: 22404326] |
| HEK293 | EC50 |
4.54 x 10-10 M
Compound: 20S(OH)D3
|
Antiproliferative activity against NHEK cells incubated for 24 hrs by [3H]thymidine incorporation assay
Antiproliferative activity against NHEK cells incubated for 24 hrs by [3H]thymidine incorporation assay
|
[PMID: 22404326] |
In Vitro
20-Hydroxyvitamin D3 (20 min) acts as a substrate for mouse CYP27B1, with a 1α-hydroxylase activity of 0.135 mol product/min/mol CYP27B1[1].
20-Hydroxyvitamin D3 (0.1-100 nM; 24 h, 48 h) dose-dependently inhibits proliferation of human HaCaT keratinocytes and HDFn, with significant effects observed at concentrations ≥0.1 nM after 24 or 48 h of treatment[1].
20-Hydroxyvitamin D3 (0.1-100 nM; 8 h, 24 h) stimulates the expression of keratinocyte differentiation marker genes involucrin, CK10, and filaggrin in human HEKn after 8 or 24 h of treatment[1].
20-Hydroxyvitamin D3 (100 nM; 48 h) significantly increases protein levels of involucrin, CK10, CK14, and catalase, promoting differentiation of human HEKn[1].
20-Hydroxyvitamin D3 (1.5 h) induces VDR translocation to the nucleus in SKMEL-188 melanoma cells, with an EC50 of 0.19 μM[1].
20-Hydroxyvitamin D3 (23 h) acts as an agonist for AhR, stimulating AhR-dependent luciferase activity in reporter cells with an EC50 of 39 nM[1].
20-Hydroxyvitamin D3 (100 nM; 8 h) significantly upregulates the expression of VDR target gene CYP24A1 and AhR target genes CYP1A1 and CYP1B1 in human HEKn[1].
20-Hydroxyvitamin D3 (100 nM; 24 h) increases the proportion of a specific CD4 T cell subpopulation (downregulated CD4, increased CD69/ICOS) in activated human PBMC[1].
20-Hydroxyvitamin D3 (substrate-to-phospholipid ratios; 1 min kinetic assays, up to 30 min time course/product identification assays) is metabolized by rat CYP24A1 in phospholipid vesicles with a catalytic efficiency of 386 min−1 (mol substrate/mol phospholipid)−1, producing primarily 20,24-dihydroxyvitamin D3 and 20,25-dihydroxyvitamin D3 without generating secondary oxidized metabolites[2].
20-Hydroxyvitamin D3 (0.1-10 nM; 2 weeks, with fresh compound added every 72 h) significantly inhibits colony formation by SKMEL-188 melanoma cells in soft agar over a 2-week period[2].
20-Hydroxyvitamin D3 (0.1-100 nM; 7 d) inhibits proliferation of HepG2 hepatocellular carcinoma cells in a concentration-dependent manner, reducing CFU of colonies larger than 0.2 mm by 54% and colonies larger than 0.5 mm by 70% at 100 nM after 7 days of treatment[3].
20-Hydroxyvitamin D3 (10-100 nM; 14 d) inhibits proliferation of MDA-MB-453 human breast carcinoma cells in soft agar in a concentration-dependent manner, reducing CFU of colonies larger than 0.2 mm by 54% at 100 nM and inhibiting formation of colonies larger than 1.5 mm by 85% at 10 nM after 14 days of treatment[3].
20-Hydroxyvitamin D3 (100 nM; 26 d) inhibits proliferation of MCF7 human breast carcinoma cells in soft agar, reducing CFU of colonies larger than 0.2 mm by 78% at 100 nM after 26 days of treatment[3].
20-Hydroxyvitamin D3 (0.1 μM; 14 days, added every 72 h) significantly inhibits monolayer colony formation of SKMel-188 human melanoma cells[4].
20-Hydroxyvitamin D3 (1-100 nM; 12 days, added every 72 h) dose-dependently inhibits anchorage-independent colony formation of SKMel-188 human melanoma cells, with IC50 values ranging from 6.91 to 19.54 nM across colony size categories[4].
20-Hydroxyvitamin D3 (10-100 nM; 24 h) dose-dependently inhibits chemotactic migration of SKMel-188 human melanoma cells at both 10,000 and 100,000 cells/well densities[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human epidermal HaCaT keratinocytes, human dermal fibroblasts (HDFn)
-
Concentration:0.1 nM, 1 nM, 10 nM,100 nM
-
Incubation Time:24 h; 48 h
-
Result:Significantly inhibited proliferation of HaCaT keratinocytes.
Significantly inhibited proliferation of HDFn.
-
Cell Line:human neonatal epidermal keratinocytes (HEKn)
-
Concentration:0.1 nM, 1 nM, 10 nM,100 nM
-
Incubation Time:8 h; 24 h
-
Result:Significantly increased expression of involucrin, CK10, and filaggrin.
Significantly increased expression of involucrin, CK10, and filaggrin.
-
Cell Line:human neonatal epidermal keratinocytes (HEKn)
-
Concentration:100 nM
-
Incubation Time:48 h
-
Result:Significantly increased the percentage of fluorescence-positive cells for involucrin, CK10, CK14, and catalase.
Significantly increased mean fluorescence per cell for involucrin, CK10, CK14, and catalase.
-
Cell Line:HepG2 hepatocellular carcinoma cells
-
Concentration:0.1 nM, 10 nM, 100 nM
-
Incubation Time:7 d
-
Result:Reduced the colony-forming units (CFU) of colonies larger than 0.2 mm by 54 ± 14% compared to vehicle control (100 nM).
Reduced CFU of colonies larger than 0.5 mm by 70 ± 20% compared to vehicle control (100 nM).
Did not significantly affect the total number of colonies larger than 0.2 mm (0.1 nM and 10 nM).
Greatly prevented the formation of colonies larger than 0.5 mm (0.1 nM and 10 nM).
-
Cell Line:SKMel-188 human melanoma cells
-
Concentration:100 nM
-
Incubation Time:14 days (added every 72 h)
-
Result:Significantly reduced the number of colonies >0.2 mm compared to vehicle control.
In Vivo
20-Hydroxyvitamin D3 (3 μg/kg; 7 days) exhibits no calcemic activity in rats[3].
20-Hydroxyvitamin D3 (3-30 μg/kg; i.p.) inhibits human melanoma tumor growth in immunocompromised NSG mice by 61% at a dose of 30 μg/kg (i.p., 5 days per week for 2 weeks) without visible toxicity, and improves animal health status relative to controls, while 3 μg/kg dose shows no significant effect[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) (7-week-old female; vitamin D-deficient diet for 2 weeks prior to tumor implantation)[4]
-
Dosage:30 μg/kg ; 3 μg/kg
-
Administration:i.p.; 5 days per week; 2 weeks
-
Result:Reduced accrued tumor volume by 61%.
Exhibited statistically significant tumor growth inhibition on days 13, 18, and 21 post-implantation via tumor volume or geometric mean of tumor dimensions.
Confirmed reduced tumor burden via bioluminescent imaging.
Showed no visible signs of toxicity.
Failed to produce a significant inhibitory effect on melanoma growth at 3 μg/kg dose.
Chemical Information
-
CAS No. 651734-12-2
-
Appearance Oil
-
Molecular Weight 400.64
-
Formula C27H44O2
-
Color Colorless to light yellow
-
SMILES
C=C1CC[C@H](O)C/C1=C/C=C2[C@@](CC[C@]3([H])[C@@](C)(O)CCCC(C)C)([H])[C@]3(C)CCC/2
-
Synonyms
20(OH)D3; 20S-Hydroxyvitamin D3
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Soft Agar Colony Formation Assay
Soft agar colony formation assay measures anchorage-independent growth, in which transformed or tumorigenic cells proliferate as colonies in a semisolid agar matrix while many non-transformed adherent cells fail to proliferate without attachment; classic studies showed that growth in semisolid medium correlates with tumorigenicity in nude mice, and later protocol papers describe the method as a stringent in vitro assay for malignant transformation. The readout is the number, size, morphology, or signal intensity of colonies formed within agar after incubation; published formats include manual colony counting after staining, 96-well or 384-well quantitative formats, DNA-binding dye detection, MTT/tetrazolium-based detection, digital image analysis, and PCR-based marker detection from soft agar cultures.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
iPSC cell differentiation
Induced pluripotent stem cells (iPSCs) are a type of cell that has similar properties to embryonic stem cells through somatic cell reprogramming.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Brzeminski P, et al. Chemical synthesis, biological activities and action on nuclear receptors of 20S(OH)D3, 20S,25(OH)2D3, 20S,23S(OH)2D3 and 20S,23R(OH)2D3. Bioorg Chem. 2022 Apr;121:105660. [Content Brief]
[2]. Tieu EW, et al. Rat CYP24A1 acts on 20-hydroxyvitamin D(3) producing hydroxylated products with increased biological activity. Biochem Pharmacol. 2012;84(12):1696-1704. [Content Brief]
[3]. Wang J, et al. 20-hydroxyvitamin D₃ inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res. 2012;32(3):739-746. [Content Brief]
[4]. Skobowiat C, et al. Noncalcemic 20-hydroxyvitamin D3 inhibits human melanoma growth in in vitro and in vivo models. Oncotarget. 2017;8(6):9823-9834. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- 20-Hydroxyvitamin D3
- 651734-12-2
- 20(OH)D3
- 20S-Hydroxyvitamin D3
- VD/VDR
- Aryl Hydrocarbon Receptor
- NF-κB
- Cytochrome P450
- CYP27B1
- SKMEL-188 melanoma cells
- MDA-MB-453 human breast carcinoma cells
- vitamin D receptor (VDR)
- HepG2 hepatocellular carcinoma cells
- IκBα
- HaCaT keratinocytes
- CYP24A1
- aryl hydrocarbon receptor (AhR)
- Inhibitor
- inhibitor
- inhibit